Vicore Pharma Holding AB

Vicore Pharma Holding AB
About Us
Change country

Follow us:
Share:
Subscribe:

About Us

Vicore is a rare disease pharmaceutical company focused on rare lung disorders and related indications. The company currently has three drug development programs, VP01, VP02 and VP03.VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (“IPF”), pulmonary fibrosis in systemic sclerosis (“SSc”) and COVID-19. VP02 is based on a new formulation and delivery route of an existing immunomodulatory compound (an “IMiD”). VP02 focuses on the underlying disease and the severe cough associated with IPF. VP01 and VP02 are also being actively evaluated for other indications within the field of interstitial lung diseases which have a significant unmet need. VP03 includes follow-up molecules to VP01. The company's shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

I-Tech signs supply agreement with Chugoku marine paints Ltd

Tue, Jul 08, 2014 09:22 CET

I-Tech has entered into a non-exclusive supply agreement with Chugoku Marine Paints Ltd (CMP) for use of I-Tech’s proprietary product, Selektope®, in commercial antifouling paints. Selektope® is to be used as the principle biocide in new products to be brought to the market by CMP. We are delighted that CMP has selected our product and identified its potential to bring enhanced value to their customers. CMPs decision marks not only an important milestone for I-Tech but also sets the starting point for antifoulings containing a new selective biocide with a repellant mode of action and

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

I-Tech signs supply agreement with Chugoku marine paints Ltd

Media